{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:06:56Z","timestamp":1793210816208,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40264-026-01691-5","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:51:01Z","timestamp":1786711861000},"page":"1477-1491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives"],"prefix":"10.1007","volume":"49","author":[{"given":"Vijay","family":"Kara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Younus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hauben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1691_CR1","unstructured":"WHO. Summary reports on proceedings minutes and final acts of the international health conference held in New York from 19 June to 22 July 1946. 1948."},{"key":"1691_CR2","unstructured":"WHO. The importance of Pharmacovigilance Safety Monitoring of medicinal products; 2002."},{"issue":"15","key":"1691_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200.","journal-title":"JAMA"},{"issue":"5","key":"1691_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"1","key":"1691_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377.","journal-title":"Drug Saf"},{"key":"1691_CR6","doi-asserted-by":"crossref","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases the notoriety bias. Drug Saf. 2007;30(10):891\u20138.","DOI":"10.2165\/00002018-200730100-00007"},{"issue":"9","key":"1691_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40264-023-01327-y","volume":"46","author":"V Kara","year":"2023","unstructured":"Kara V, Powell G, Mahaux O, Jayachandra A, Nyako N, Golds C, et al. Finding needles in the haystack: clinical utility score for prioritisation (CUSP), an automated approach for identifying spontaneous reports with the highest clinical utility. Drug Saf. 2023;46(9):847\u201355.","journal-title":"Drug Saf"},{"key":"1691_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-031-51089-2_12","volume-title":"Principles and practice of pharmacovigilance and drug safety","author":"F van Hunsel","year":"2024","unstructured":"van Hunsel F, Younus MM, Cox AR. Patient and public involvement in pharmacovigilance. In: Jose J, Cox AR, Paudyal V, editors. Principles and practice of pharmacovigilance and drug safety. Cham: Springer International Publishing; 2024. p. 273\u201393."},{"key":"1691_CR9","unstructured":"ICH. Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D. 2003."},{"issue":"9","key":"1691_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40264-025-01553-6","volume":"48","author":"V Kara","year":"2025","unstructured":"Kara V, Van Hunsel F, Bate A, van Puijenbroek E. The role of adverse event follow-up in advancing the knowledge of medicines and vaccines safety: a scoping review. Drug Saf. 2025;48(9):977\u201391.","journal-title":"Drug Saf"},{"key":"1691_CR11","unstructured":"EMA. GVP Module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). In: Agency EM, editor.; 2017."},{"key":"1691_CR12","unstructured":"EMA. Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ). In: EMA, editor. EMA\/PRAC\/490455\/2023; 2025."},{"key":"1691_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.901355","volume":"13","author":"G Powell","year":"2022","unstructured":"Powell G, Kara V, Painter JL, Schifano L, Merico E, Bate A. Engaging patients via online healthcare fora: three pharmacovigilance use cases. Front Pharmacol. 2022;13:901355.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1691_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s43441-024-00711-9","volume":"59","author":"G Powell","year":"2025","unstructured":"Powell G, Kara V, Naranjo D, Kulkarni M, Best-Sule K, Coster T, et al. Testing the feasibility of a digital point of care solution for the trusted near real-time bidirectional exchange of novel and informative adverse event information. Ther Innov Regul Sci. 2025;59(1):124\u201334.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"1691_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10916-024-02070-2","volume":"48","author":"H Abedian Kalkhoran","year":"2024","unstructured":"Abedian Kalkhoran H, Zwaveling J, van Hunsel F, Kant A. An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records. J Med Syst. 2024;48(1):51.","journal-title":"J Med Syst"},{"key":"1691_CR16","unstructured":"CIOMS. CIOMS V Current Challenges in Pharmacovigilance: Pragmatic Approaches; 2001."},{"issue":"4","key":"1691_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/picr.PICR_120_17","volume":"8","author":"R Bhangale","year":"2017","unstructured":"Bhangale R, Vaity S, Kulkarni N. A day in the life of a pharmacovigilance case processor. Perspect Clin Res. 2017;8(4):192\u20135.","journal-title":"Perspect Clin Res"},{"issue":"1","key":"1691_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12325-023-02699-4","volume":"41","author":"GK Vemula","year":"2024","unstructured":"Vemula GK, Badale P, Mavrogenis P, Lalande-Luesink I, Borkowski M, Lewis DJ. A risk-based approach for safety case follow-up of adverse event reports in pharmacovigilance. Adv Ther. 2024;41(1):82\u201391.","journal-title":"Adv Ther"},{"key":"1691_CR19","unstructured":"Brand JS GO, Sartori D, Sk\u00f6ld H, Bergvall T, Sandberg L, Wallberg M, Hjelmstr\u00f6m P, Nor\u00e9n GN. Recent trends in global adverse event reporting: a descriptive analysis of VigiBase. 2024."},{"key":"1691_CR20","unstructured":"Council for International Organizations of Medical S. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII: CIOMS; 2010."},{"issue":"5","key":"1691_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.clinthera.2018.02.013","volume":"40","author":"J Price","year":"2018","unstructured":"Price J. Pharmacovigilance in crisis: drug safety at a crossroads. Clin Ther. 2018;40(5):790\u20137.","journal-title":"Clin Ther"},{"issue":"2","key":"1691_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"7","key":"1691_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore). 2023;102(7):e32829.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1691_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"1691_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1079\/PNS2004399","volume":"63","author":"F Rabiee","year":"2004","unstructured":"Rabiee F. Focus-group interview and data analysis. Proc Nutr Soc. 2004;63(4):655\u201360.","journal-title":"Proc Nutr Soc"},{"key":"1691_CR26","volume-title":"Focus groups : a practical guide for applied research","author":"RA Krueger","year":"2009","unstructured":"Krueger RA, Casey MA. Focus groups\u202f: a practical guide for applied research. 4th ed. Los Angeles: SAGE; 2009.","edition":"4th ed"},{"key":"1691_CR27","unstructured":"Commission E. Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation). OJ L;119:1\u201388 (2016). 2016."},{"issue":"5","key":"1691_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2288-5-37","volume":"1","author":"RB Akins","year":"2005","unstructured":"Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005;1(5):37.","journal-title":"BMC Med Res Methodol"},{"key":"1691_CR29","unstructured":"WHO. Countries\/areas by WHO region. Available from: https:\/\/apps.who.int\/violence-info\/Countries%20and%20areas%20by%20WHO%20region%20-%2012bfe12.pdf."},{"key":"1691_CR30","unstructured":"Atlas.ti. The Guide to Interview Analysis. [cited April 2025]. https:\/\/atlasti.com\/guides\/interview-analysis-guide\/verbatim-transcription."},{"key":"1691_CR31","unstructured":"GmbH AtSSD. ATLAS.ti Eindows (version 25.0.1) [Qualitative data analysis software]. 2025."},{"issue":"3","key":"1691_CR32","doi-asserted-by":"publisher","DOI":"10.1590\/0034-7167-2019-0250","volume":"73","author":"J Soratto","year":"2020","unstructured":"Soratto J, Pires DEP, Friese S. Thematic content analysis using ATLAS.ti software: potentialities for researchs in health. Rev Bras Enferm. 2020;73(3):e20190250.","journal-title":"Rev Bras Enferm"},{"key":"1691_CR33","doi-asserted-by":"crossref","unstructured":"Sutton J, Austin Z. Qualitative research: data collection, analysis, and management. Can J Hosp Pharm. 2015;68(3).","DOI":"10.4212\/cjhp.v68i3.1456"},{"key":"1691_CR34","doi-asserted-by":"publisher","first-page":"03.CP.3.4","DOI":"10.2466\/03.CP.3.4","volume":"3","author":"H Ando","year":"2014","unstructured":"Ando H, Cousins R, Young C. Achieving saturation in thematic analysis: development and refinement of a codebook. Compr Psychol. 2014;3:03.CP.3.4.","journal-title":"Compr Psychol"},{"key":"1691_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1691_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions. Drug Saf. 2008;31(1):21\u201337.","journal-title":"Drug Saf"},{"issue":"2","key":"1691_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"1691_CR38","unstructured":"EMA. EMA\/CHMP\/PRAC\/148869\/2025 Reflection paper on patient experience data (draft). In: (EMA) EMA, editor.; 2025."},{"issue":"7","key":"1691_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00228-022-03326-x","volume":"78","author":"R Li","year":"2022","unstructured":"Li R, Curtis K, Van C, Tabish Razi Zaidi S, Yeo CY, Arun Kali C, et al. Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the theoretical domains framework. Eur J Clin Pharmacol. 2022;78(7):1165\u201375.","journal-title":"Eur J Clin Pharmacol"},{"issue":"329","key":"1691_CR40","first-page":"128","volume":"7","author":"S Konishi","year":"2025","unstructured":"Konishi S, Sugimoto K, Asai R, Yoshioka Y, Wada S, Okada K, et al. EMR-integrated data retrieval system: reducing workload in adverse drug event reporting. Stud Health Technol Inform. 2025;7(329):128\u201332.","journal-title":"Stud Health Technol Inform."},{"issue":"7","key":"1691_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070275","volume":"13","author":"T Osawa","year":"2023","unstructured":"Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, et al. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). BMJ Open. 2023;13(7):e070275.","journal-title":"BMJ Open"},{"issue":"7","key":"1691_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061725","volume":"12","author":"R Kiguba","year":"2022","unstructured":"Kiguba R, Mwebaza N, Ssenyonga R, Ndagije HB, Nambasa V, Katureebe C, et al. Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open. 2022;12(7):e061725.","journal-title":"BMJ Open"},{"issue":"1","key":"1691_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pds.5542","volume":"32","author":"ER Parracha","year":"2023","unstructured":"Parracha ER, Advinha AM, Lopes MJ, Oliveira-Martins S. Mobile apps for quick adverse drug reaction report: a scoping review. Pharmacoepidemiol Drug Saf. 2023;32(1):19\u201327.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1691_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40264-017-0509-2","volume":"40","author":"EI Ralph","year":"2017","unstructured":"Ralph EI. Causality assessment in pharmacovigilance: still a challenge. Drug Saf. 2017;40(5):365\u201372.","journal-title":"Drug Saf"},{"issue":"5","key":"1691_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40264-024-01403-x","volume":"47","author":"D Sartori","year":"2024","unstructured":"Sartori D, Aronson JK, Erlanson N, Nor\u00e9n GN, Onakpoya IJ. A comparison of signals of designated medical events and non-designated medical events: results from a scoping review. Drug Saf. 2024;47(5):475\u201385.","journal-title":"Drug Saf"},{"issue":"4","key":"1691_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283\u201394.","journal-title":"Drug Saf"},{"key":"1691_CR47","unstructured":"CIOMS IX Practical approaches to risk minimisation for medicinal products: CIOMS Working Group IX report. Council for International Organizations of Medical Sciences (CIOMS); 2014."},{"issue":"2","key":"1691_CR48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bcp.14139","volume":"86","author":"SA Woo","year":"2020","unstructured":"Woo SA, Cragg A, Wickham ME, Villanyi D, Scheuermeyer F, Hau JP, et al. Preventable adverse drug events: descriptive epidemiology. Br J Clin Pharmacol. 2020;86(2):291\u2013302.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"1691_CR49","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1517\/14740338.2014.947260","volume":"13","author":"C Leporini","year":"2014","unstructured":"Leporini C, De Sarro G, Russo E. Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf. 2014;13(Suppl 1):S41-55.","journal-title":"Expert Opin Drug Saf"},{"key":"1691_CR50","unstructured":"EMA. GvP Module V\u2014risk management systems (Rev 2). 2017."},{"issue":"7","key":"1691_CR51","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/bcp.14255","volume":"86","author":"A Fabbri","year":"2020","unstructured":"Fabbri A, O\u2019Keeffe M, Moynihan R, M\u00f8llebaek M, Mohammad A, Bhasale A, et al. Media coverage of drug regulatory agencies\u2019 safety advisories: a case study of citalopram and denosumab. Br J Clin Pharmacol. 2020;86(7):1416\u201329.","journal-title":"Br J Clin Pharmacol"},{"key":"1691_CR52","volume":"49","author":"V Jaiswal","year":"2023","unstructured":"Jaiswal V, Mukherjee D, Peng Ang S, Kainth T, Naz S, Babu Shrestha A, et al. COVID-19 vaccine-associated myocarditis: analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. Int J Cardiol Heart Vasc. 2023;49:101280.","journal-title":"Int J Cardiol Heart Vasc."},{"key":"1691_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2024.102758","volume":"61","author":"AJ Feeney","year":"2024","unstructured":"Feeney AJ, Goad JA, Flaherty GT. Global perspective of the risks of falsified and counterfeit medicines: a critical review of the literature. Travel Med Infect Dis. 2024;61:102758.","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"1691_CR54","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509.","journal-title":"Br J Clin Pharmacol"},{"key":"1691_CR55","unstructured":"CIOMS XIV Artificial intelligence in Pharmacovigilance. CIOMS Working Group XIV report. Council for International Organizations of Medical Sciences (CIOMS); 2025."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01691-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:42:22Z","timestamp":1792039342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01691-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01691-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VK and AB are employed by GSK also hold shares\/stocks\/stock options in the company. MH is an employee of Merck KGaA and holds stock\/stock options in Merck KGaA and other pharmaceutical companies. MY has no conflicts of interest. AB, FVH, MY and EVP are Editorial Board members of\n                      Drug Safety\n                      . None were involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VK, FVH, AB and EVP were involved in the conception and design of the study. VK and FVH participated in thematic analysis. VK, FVH, AB and EVP authors were involved in the analysis or interpretation of the data. All authors reviewed and commented on drafts of the manuscript for intellectual content and gave final approval to submit for publication. All authors attest they meet the ICMJE criteria for authorship. All authors read and approved the final version.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supporting materials used in the study are available as Supplementary Material, further inquiries can be directed to the corresponding author.","order":4,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was being conducted as part of a PhD programme via the University of Groningen. If a study in the Netherlands is subject to the Medical Research Involving Human Subjects Act (WMO), it must undergo a review by an accredited Medical Research Ethics Committee or the Central Committee on Research Involving Human Subjects (CCMO). This study does not fall under the WMO. In addition, the UK Research and Innovation Medical Research Council questionnaire was completed and it was determined that ethics approval was not required.","order":5,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was obtained prior to participation within the study.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were provided the opportunity to review the manuscript prior to submission. No further approval or consent was needed for this study.","order":7,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}